title: ONT-093 (Ontogen).
abstract: Ontogen is developing ONT-093 (formerly OC-144-093), a P-glycoprotein pump inhibitor, for the potential reversal of multidrug resistance in patients undergoing cancer chemotherapy. The compound is also being evaluated for its potential enhancement of the oral bioavailability of drugs that are P-glycoprotein substrates requiring either high dosage forms or intravenous administration, and for the potential improvement of central nervous system penetration of P-glycoprotein substrate drugs.
authors.affiliation: Xenova Ltd, 957 Buckingham Avenue, Slough, Berkshire, SL1 4NL, UK. prakash_mistry@xenova.co.uk
authors.forename: Prakash
authors.initials: P
authors.lastname: Mistry
authors.forename: Adrian
authors.initials: A
authors.lastname: Folkes
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D018432:Drug Resistance, Multiple / Q000502:physiology; D006801:Humans; D007093:Imidazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
chemical_list: D007093:Imidazoles; C410029:OC 144-093